Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma

Gündüz, Kamer; Günay, Ümran; İnanır, Işıl; Gençoğlan, Gülsüm; Temız, Peyker

doi:10.3315/jdcr.2012.1099

Cited by 10 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some case reports showed successful treatment of single classic KS in HIV-negative patients with 3 times per week application under occlusion for 12 weeks. 9,17 Some needed daily application for 4 months in 1 HIV patient, 12 and nightly under occlusion for multiple classic KS in an HIV-negative patient that required 1 year of application before clearance. 15 The treatment period may be the other significant point to increase the efficacy of imiquimod, which was applied for only 12 weeks in our study.…”

Section: Discussionmentioning

confidence: 99%

“…It has been found to be highly effective against KS in some case reports in the literature. [9][10][11][12][13][14][15][16][17] There is only 1 trial wherein imiquimod in KS was investigated for its antitumour activity, showing antitumour activity in 8 of 17 patients. 2 Our study is designed to evaluate the effect of imiquimod, which is distinguished from other local treatment methods by its at-home application, on classic KS lesions compared with cryotherapy, which is one of the most-used treatment methods for KS in our department.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

et al. 2019

View full text Add to dashboard Cite

Background: Classic Kaposi sarcoma usually remains on the skin and has a slow progression; thus, local treatment methods are preferable. Imiquimod is an immunomodulatory agent with antiviral, antitumoural, and antiangiogenic properties that is expedient against Kaposi sarcoma. Objectives: We aimed to clarify whether imiquimod is effective on classic Kaposi sarcoma lesions by comparing imiquimod treatment with cryotherapy, which is the most-used treatment method in our department for this disease. Method: Patients with classic Kaposi sarcoma were included. All lesions of each patient were evaluated and measured by the blinded investigator considering infiltration and surface diameters. Then, lesions were categorized into 2 groups by the other investigator (nonblinded), and imiquimod 5% cream was administered 3 times per week without occlusion in 1 group. Cryotherapy was performed every 3 weeks in the other group. All lesions were reevaluated and measured at the end of 12 weeks by the blinded investigator. Initial and last measurements were compared between the treatment methods. Results: Fifty lesions of 8 patients were included in this study. Imiquimod and cryotherapy were applied to 26 and 24 lesions, respectively. At the end of the study, statistically significant decreases were detected in all scores between weeks 0 and 12 with both treatment methods. Mean percentages of change in scores were not significantly different between the methods. Conclusions: Based on a limited number of patients and lesions treated, we believe imiquimod may be a suitable option to use for the treatment of classic Kaposi sarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…87,88 Case reports have shown that imiquimod cream can be safe and effective in some patients with classic or transplant-associated Kaposi sarcoma. [89][90][91][92][93][94] In a single-center, open-label, phase I/II trial, 17 HIV-negative patients with Kaposi sarcoma received imiquimod 5% cream 3 times per week for 24 weeks. 95 The response rate was 47%.…”

Section: Topical Therapiesmentioning

confidence: 99%

AIDS-Related Kaposi Sarcoma, Version 2.2019

Reid

Suneja

Ambinder

et al. 2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.

show abstract

“…Imiquimod acts by activating cytokines that have an antagonistic role in angiogenesis, pro-angiogenic factor down-regulation and induction of apoptosis in endothelial cells. [ 39 ] Goiriz et al [ 40 ] reported a successful treatment outcome using 5% imiquimod cream in an 87-year-old man with widespread nodules of classical KS on both his lower limbs. Another patient with successful outcome following the usage of 5% imiquimod cream in a thrice weekly schedule for localized KS under occlusion for 8 h for a period of 3 months has been reported by Bernardini et al [ 41 ]…”

Section: Uses Of Imiquimod In Cutaneous Premalignant and Malignant Comentioning

confidence: 99%

Imiquimod - Its role in the treatment of cutaneous malignancies

Bubna

2015

Indian J Pharmacol

View full text Add to dashboard Cite

Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response modifier activity, when topically used. This characteristic property of imiquimod has led to its use in a number of applications in dermatology, particularly in cutaneous malignancies, where it has been found to be effective and safe. Currently, additional mechanisms for its activity in actinic keratosis, basal cell carcinoma, and invasive squamous cell carcinoma have been elucidated. Its usage for cutaneous metastasis in breast cancer has been a further addition to its therapeutic armamentarium recently.

show abstract

Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma

Cited by 10 publications

References 6 publications

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

AIDS-Related Kaposi Sarcoma, Version 2.2019

Imiquimod - Its role in the treatment of cutaneous malignancies

Contact Info

Product

Resources

About